Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

A design strategy can ensure conflicting properties are managed appropriately for multi-API controlled-release formulations.

Combo Drugs Require a Complex Design Approach

Empty and prefilled syringes must pass a range of quality control tests.

Test Methods and Quality Control for Prefilled Syringes

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Using training devices may ease patient anxiety about using autoinjectors and prefilled syringes, potentially leading to improved patient adherence.

Autoinjector Training May Lead to Patient Adherence

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

FDA Commissioner Scott Gottlieb has been promoting drug market competition in recent months that includes new guidance documents and targeted advisories to support R&D of complex drugs and combination products. 

Regulatory Developments in Combination Products

Pharmaceutical companies are developing new strategies to address the ever-increasing development costs for new drug therapies and maximize the value of their existing drug portfolio.

Innovating Lifecycle Management with Data-Driven and Enabling Technologies

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Formulation characteristics must be optimized, following device selection, to achieve the desired performance for the capsule loaded in the dry powder inhaler. 

Developing Capsules for DPIs

A new oral delivery method developed by the Harvard John A. Paulson School of Engineering and Applied Sciences could change the way diabetics regulate blood sugar levels.

Ionic Pill Could Replace Daily Injections for Diabetics

The company is developing a pipeline of combination therapies using its patented polymer-based matrix delivery system, known as TAOS (targeted orchestrated signalling matrix).

Locate Therapeutics Achieves ISO 13845 Certification for Development and Control of Manufacturing for Resorbable Biomaterials

The company is expanding its 380,000-square-feet Molex Little Rock facility to include a FDA-registered manufacturing center of excellence for connected health and drug-delivery devices.

Phillips-Medisize Invests in Manufacturing Center of Excellence for Connected Health and Drug-Delivery Devices

Medherant has developed an improved instrument for testing drug release from transdermal patches.

Formulation and Drug Delivery, Combination Drugs